Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Antidepressant Drugs | Research article

Conditional power of antidepressant network meta-analysis

Author: Lisa Holper

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

Conditional power of network meta-analysis (NMA) can support the planning of randomized controlled trials (RCTs) assessing medical interventions. Conditional power is the probability that updating existing inconclusive evidence in NMA with additional trial(s) will result in conclusive evidence, given assumptions regarding trial design, anticipated effect sizes, or event probabilities.

Methods

The present work aimed to estimate conditional power for potential future trials on antidepressant treatments. Existing evidence was based on a published network of 502 RCTs conducted between 1979-2018 assessing acute antidepressant treatment in major depressive disorder (MDD). Primary outcomes were efficacy in terms of the symptom change on the Hamilton Depression Scale (HAMD) and tolerability in terms of the dropout rate due to adverse events. The network compares 21 antidepressants consisting of 231 relative treatment comparisons, 164 (efficacy) and 127 (tolerability) of which are currently assumed to have inconclusive evidence.

Results

Required sample sizes to achieve new conclusive evidence with at least 80% conditional power were estimated to range between N = 894 - 4190 (efficacy) and N = 521 - 1246 (tolerability). Otherwise, sample sizes ranging between N = 49 - 485 (efficacy) and N = 40 - 320 (tolerability) may require stopping for futility based on a boundary at 20% conditional power. Optimizing trial designs by considering multiple trials that contribute both direct and indirect evidence, anticipating alternative effect sizes or alternative event probabilities, may increase conditional power but required sample sizes remain high. Antidepressants having the greatest conditional power associated with smallest required sample sizes were identified as those on which current evidence is low, i.e., clomipramine, levomilnacipran, milnacipran, nefazodone, and vilazodone, with respect to both outcomes.

Conclusions

The present results suggest that conditional power to achieve new conclusive evidence in ongoing or future trials on antidepressant treatments is low. Limiting the use of the presented conditional power analysis are primarily due to the estimated large sample sizes which would be required in future trials as well as due to the well-known small effect sizes in antidepressant treatments. These findings may inform researchers and decision-makers regarding the clinical relevance and justification of research in ongoing or future antidepressant RCTs in MDD.

Available only for authorised users

De Meulemeester J, Fedyk M, Jurkovic L, Reaume M, Dowlatshahi D, Stotts G, Shamy M. Many randomized clinical trials may not be justified: a cross-sectional analysis of the ethics and science of randomized clinical trials. J Clin Epidemiol. 2018; 97:20–5. https://doi.org/10.1016/j.jclinepi.2017.12.027.PubMedCrossRef

Sertkaya A, Wong H-H, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the united states. Clinical Trials. 2016; 13(2):117–26. https://doi.org/10.1177/1740774515625964.PubMedCrossRef

Moore TJ, Zhang H, Anderson G, Alexander G. Estimated costs of pivotal trials for novel therapeutic agents approved by the us food and drug administration, 2015-2016. JAMA Intern Med. 2018; 178(11):1451–7. https://doi.org/10.1001/jamainternmed.2018.3931.PubMedPubMedCentralCrossRef

Langan D, Higgins J, Gregory W, Sutton A. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol. 2012; 65(5):511–9. https://doi.org/10.1016/j.jclinepi.2011.10.009.PubMedCrossRef

Sutton AJ, Cooper N, Jones DR, Lambert P, Thompson J, Abrams KR. Evidence-based sample size calculations based upon updated meta-analysis. Statistics in Medicine. 2007; 26(12):2479–500. https://doi.org/10.1002/sim.2704.PubMedCrossRef

Roloff V, Higgins J, Sutton AJ. Planning future studies based on the conditional power of a meta-analysis. Stat Med. 2013; 32(1):11–24. https://doi.org/10.1002/sim.5524.PubMedCrossRef

Nikolakopoulou A, Mavridis D, Salanti G. Using conditional power of network meta-analysis (nma) to inform the design of future clinical trials. Biom J. 2014; 56(6):973–90. https://doi.org/10.1002/bimj.201300216.PubMedCrossRef

Salanti G, Nikolakopoulou A, Sutton AJ, Reichenbach S, Trelle S, Naci H, Egger M. Planning a future randomized clinical trial based on a network of relevant past trials. Trials. 2018; 19(1):365. https://doi.org/10.1186/s13063-018-2740-2.PubMedPubMedCentralCrossRef

Cohen J. Statistical Power Analysis for the Behavioral Sciences. NJ: Lawrence Erlbaum Associates; 1988, pp. 1–17.

10.

Walter SD, Han H, Guyatt GH, Bassler D, Bhatnagar N, Gloy V., Schandelmaier S, Briel M. A systematic survey of randomised trials that stopped early for reasons of futility. BMC Med Res Methodol. 2020; 20(1):10. https://doi.org/10.1186/s12874-020-0899-1.PubMedPubMedCentralCrossRef

11.

Cipriani A. Cipriani et al_GRISELDA_Lancet 2018_Open dataset. Mendeley Data, V2. 2018. https://doi.org/10.17632/83rthbp8ys.2.

12.

Cipriani A, Furukawa T, Salanti G, Chaimani A, Atkinson L, Ogawa Y, Leucht S, Ruhe H, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H., Shinohara K, Tajika A, Ioannidis JPA, Geddes J. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357–66. https://doi.org/10.1016/S0140-6736(17)32802-7.PubMedPubMedCentralCrossRef

13.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23(1):56–62.PubMedPubMedCentralCrossRef

14.

CSPC ZhongQi Pharmaceutical Technology Co. Ltd.Study of Desvenlafaxine in Treating Major Depressive Disorder (Clinicaltrials.gov Identifier NCT04364997). 2020. https://clinicaltrials.gov/ct2/show/NCT04364997.

15.

University of Texas Southwestern Medical Center, University of Washington, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Combination of Novel Therapies for CKD Comorbid Depression (Clinicaltrials.gov Identifier NCT04422652). 2020. https://ClinicalTrials.gov/show/NCT04422652.

16.

Mochida Pharmaceutical Company Ltd. |Pfizer. A Study of MD-120 in Patients With Depression (Clinicaltrials.gov Identifier NCT04345471). 2020. https://ClinicalTrials.gov/show/NCT04345471.

17.

Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder (Clinicaltrials.gov Identifier NCT03538691). 2021. https://ClinicalTrials.gov/show/NCT03538691.

18.

Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of lu aa21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012; 15(5):589–600. https://doi.org/10.1017/s1461145711001027.PubMedCrossRef

19.

Jain R, Mahableshwarkar A, Jacobsen PL, Chen Y, Thase M. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(2):313–21. https://doi.org/10.1017/s1461145712000727.PubMedCrossRef

20.

Mahableshwarkar A, Jacobsen P, Chen Y, Serenko M, Trivedi M. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with mdd. Psychopharmacology (Berl). 2015; 232(12):2061–70. https://doi.org/10.1007/s00213-014-3839-0.CrossRef

21.

Mahableshwarkar A, Jacobsen P, Serenko M, Chen Y, Trivedi M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5):583–91. https://doi.org/10.4088/JCP.14m09337.PubMedCrossRef

22.

Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of lu aa21004 in acute treatment of major depressive disorder (mdd). Eur Neuropsychopharmacol. 2012; 22(7):482–91. https://doi.org/10.1016/j.euroneuro.2011.11.008.PubMedCrossRef

23.

Henigsberg N, Mahableshwarkar A, Jacobsen P, Chen Y, Thase M. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of lu aa21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7):953–9. https://doi.org/10.4088/JCP.11m07470.PubMedCrossRef

24.

Katona C, Hansen T, Olsen C. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of lu aa21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27:215–23. https://doi.org/10.1097/YIC.0b013e3283542457.PubMedCrossRef

25.

Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (lu aa21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29(3):138–49. https://doi.org/10.1097/yic.0000000000000018.PubMedPubMedCentralCrossRef

26.

Jacobsen P, Mahableshwarkar A, Serenko M, Chan S, Trivedi M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry. 2015; 76(5):575–82. https://doi.org/10.4088/JCP.14m09335.PubMedCrossRef

27.

NCT, 01255787. Efficacy and safety study of vortioxetine (lu aa21004) for treatment of major depressive disorder. https://doi.org/https://clinicaltrials.gov/ct2/show/NCT01255787. Accessed 2020.

28.

NCT, 01355081. Efficacy study of vortioxetine (lu aa21004) for treatment of major depressive disorder. https://doi.org/https://clinicaltrials.gov/ct2/show/NCT01355081. Accessed 2020.

29.

McIntyre R, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10):1557–67. https://doi.org/10.1017/S1461145714000546.PubMedCrossRef

30.

Wang G, Gislum M, Filippov G, Montgomery S. Comparison of vortioxetine versus venlafaxine xr in adults in asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015; 31(4):785–94. https://doi.org/10.1185/03007995.2015.1014028.PubMedCrossRef

31.

NCT, 02279966. Efficacy of vortioxetine on cognitive dysfunction in working patients with major depressive disorder. https://doi.org/https://clinicaltrials.gov. Accessed 2020.

32.

Mahableshwarkar A, Zajecka J, Jacobson W, Chen Y, Keefe R. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacol. 2015; 40(8):2025–37. https://doi.org/10.1038/npp.2015.52.CrossRef

33.

Mahableshwarkar A, Jacobsen P, Chen Y. A randomized, double-blind trial of 2.5mg and 5mg vortioxetine versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3):217–26. https://doi.org/10.1185/03007995.2012.761600.PubMedCrossRef

34.

Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar A. Randomized, double-blind, placebo-controlled 8-week trialof the efficacy, safety, and tolerability of 5, 10, and 20 mg day vortioxetine in adults with major depressive disorder. Psychiatry and Clinical Neurosciences. 2018; 72(2):64–72.PubMedCrossRef

35.

NCT, 04448431. Comparison of vortioxetine and desvenlafaxine in adult patients suffering from depression. https://doi.org/https://ClinicalTrials.gov/show/NCT04448431. Accessed 2020.

36.

Feiger AD, Tourian K, Rosas GR, Padmanabhan S. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectrums. 2009; 14(1):41–50. https://doi.org/10.1017/S1092852900020046.PubMedCrossRef

37.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian K. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007; 22(6).

38.

Liebowitz M, Yeung P, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007; 68(11):1663–72.PubMedCrossRef

39.

Kornstein SG, Jiang Q, Reddy S, Musgnung J, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010; 71(8):1088–96.PubMedCrossRef

40.

Soares CN, Thase M, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan P, Kane CP, Cohen L. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010; 17(4):700–11. https://doi.org/10.1097/gme.0b013e3181d88962.PubMedCrossRef

41.

Wang Z, Xu X, Tan Q, Li K, Ma C, Xie S, Gao C, Wang G, Li H. Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial. Shanghai archives of psychiatry. 2015; 27(4):228–36.PubMedPubMedCentral

42.

Khazaie H, Rezaie L, Rezaei Payam N, Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial. Gen Hosp Psychiatry. 2015; 37(1):40–5. https://doi.org/10.1016/j.genhosppsych.2014.10.010.PubMedCrossRef

43.

Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Clin Drug Investig. 2007; 27(7):481–92. https://doi.org/10.2165/00044011-200727070-00005.

44.

H. Lundbeck A/S. Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder (Clinicaltrials.gov Identifier NCT02279966). 2017. https://ClinicalTrials.gov/show/NCT02279966.

45.

Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C. J Clin Psychiatry. 1992; 53 Suppl:30–2.

46.

Claghorn J. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. J Clin Psychiatry. 1992; 53 Suppl:33–5.PubMed

47.

Smith W, Glaudin V. A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry. 1992; 53(Suppl):36–9.PubMed

48.

Moher D, Liberati A, Tetzlaff J, Altman D. The PG Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. PLOS Med. 2009; 6(7):1000097. https://doi.org/10.1371/journal.pmed.1000097.CrossRef

49.

Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ Clin Res ed. 2005; 331(7509):155–7. https://doi.org/10.1136/bmj.331.7509.155.CrossRef

50.

Altman D, Royston P. The cost of dichotomising continuous variables. BMJ Clin Res ed. 2006; 332(7549):1080. https://doi.org/10.1136/bmj.332.7549.1080.CrossRef

51.

Hengartner M. Methodological flaws, conflicts of interest, and scientific fallacies: Implications for the evaluation of antidepressants’ efficacy and harm. Frontiers in psychiatry. 2017; 8:275. https://doi.org/10.3389/fpsyt.2017.00275.PubMedPubMedCentralCrossRef

52.

MacCallum R, Zhang S, Preacher KJ, Rucker D. Psychol Methods. 2002; 7(1):19–40. https://doi.org/10.1037/1082-989X.7.1.19.

53.

Furukawa T, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, Hayasaka Y, Chaimani A, Salanti G. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016; 3(11):1059–66. https://doi.org/10.1016/S2215-0366(16)30307-8.PubMedCrossRef

54.

Nikolakopoulou A, Mavridis D, Salanti G. Planning future studies based on the precision of network meta-analysis results. Stat Med. 2016; 35(7):978–1000. https://doi.org/10.1002/sim.6608.PubMedCrossRef

55.

R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. https://www.R-project.org/.

56.

Borenstein M, Hedges L, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis.Wiley; 2009.

57.

Hengartner M, Plöderl M. Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work: Effect size and method bias matter!Front Psychiatry. 2018; 9:517. https://doi.org/10.3389/fpsyt.2018.00517.PubMedPubMedCentralCrossRef

58.

Salanti G, Nikolakopoulou A. Actively Living Network Meta-Analysis, Working Paper, Institute of Social and Preventive Medicine (ISPM), University of Bern. 2021. https://www.ispm.unibe.ch/e93945/e93947/e451597/e488010/e488012/pane680818/e680822/EBAR_framework_description_paper_eng.pdf.

59.

Weber K, Lasch F, Koch A. Stat Med. 2018; 37(8):1402–4. https://doi.org/10.1002/sim.7595.

60.

The European Agency for the Evaluation of Medicinal Products. Application with 1. Meta-analyses; 2. One pivotal study, Reference number CPMP/EWP/2330/99. 2001. https://www.ema.europa.eu/en/application-1-metaanalyses-2-one-pivotal-study.

Title: Conditional power of antidepressant network meta-analysis
Author: Lisa Holper
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Antidepressant Drugs
Antidepressant Drugs
Vortioxetine
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03094-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Conditional power of antidepressant network meta-analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Borderline personality disorder and adolescent suicide attempt: the mediating role of emotional dysregulation

Association between impulsivity and orthorexia nervosa / healthy orthorexia: any mediating effect of depression, anxiety, and stress?

Mechanisms of rumination change in adolescent depression (RuMeChange): study protocol for a randomised controlled trial of rumination-focused cognitive behavioural therapy to reduce ruminative habit and risk of depressive relapse in high-ruminating adolescents

Core components and strategies for suicide and risk management protocols in mental health research: a scoping review

Symptoms of anxiety disorders in Iranian adolescents with hearing loss during the COVID-19 pandemic

Assessment of depression, anxiety and stress levels in the Ecuadorian general population during social isolation due to the COVID-19 outbreak: a cross-sectional study